CAS |
No.53716-49-7 |
中文名称 |
卡洛芬 |
英文名称 |
Carprofen |
分子式 |
C15H12ClNO2 |
分子量 |
273.71 |
溶解性 |
Soluble in DMSO ≥3mg/mL |
纯度 |
≥98% |
外观(性状) |
White to off-white Solid |
储存条件 |
Powder:2-8℃,2 years;Insolvent(母液):-20℃,6 months;-80℃,1 year |
EC |
EINECS 258-712-4 |
MDL |
MFCD00079028 |
SMILES |
CC(C1=CC2=C(C=C1)C3=C(N2)C=CC(=C3)Cl)C(=O)O |
InChIKey |
PUXBGTOOZJQSKH-UHFFFAOYSA-N |
InChI |
InChI=1S/C15H12ClNO2/c1-8(15(18)19)9-2-4-11-12-7-10(16)3-5-13(12)17-14(11)6-9/h2-8,17H,1H3,(H,18,19) |
PubChem CID |
2581 |
靶点 |
COX;FAAH |
通路 |
Immunology & Inflammation;Metabolic Enzyme&Protease |
背景说明 |
是一种非甾体类抗炎化合物,为多靶点 FAAH/COX 抑制剂,能够抑制 COX-2,COX-1 和 FAAH 的活性。 |
生物活性 |
Carprofen 是一种非甾体抗炎药,是一种多靶点 FAAH/COX 抑制剂,对 COX-2、COX-1 和 FAAH 的 IC50 分别为 3.9 μM、22.3 μM 和 78.6 μM。[1] |
IC50 |
COX-1: 22.3μM(IC50);COX-2: 3.9μM(IC50);FAAH: 78.6μM(IC50)[1] |
In Vitro |
Carprofen reduce apoptosis in cells originating from canine cruciate ligaments. Carprofen(10 μg/mL)had the greatest cytoprotective effects for cranial(CCL)and caudal(CaCL)cells.[2] |
In Vivo |
Carprofen act in vivo on target tissues as COX-1-sparing drugs by sparing gastric PGE1 and PGE2 synthesis and production of TXB2 by platelets. Carprofen significantly suppressed prostaglandin(PG)E2 concentrations in blood at days 3 and 10,compared with baseline.[3] |
数据来源文献 |
[1]. Favia AD,et al. Identification and characterization of carprofen as a multitarget fatty acid amide hydrolase/cyclooxygenase inhibitor. J Med Chem. 2012 Oct 25;55(20):8807-26. [2]. Waldherr K,et al. In vitro cytoprotective effects of acetylsalicylic acid,carprofen,meloxicam,or robenacoxib against apoptosis induced by sodium nitroprusside in canine cruciate ligament cells. Am J Vet Res. 2012 Nov;73(11):1752-8. [3]. Sessions JK,et al. In vivo effects of carprofen,deracoxib,and etodolac on prostanoid production in blood,gastric mucosa,and synovial fluid in dogs with chronic osteoarthritis. Am J Vet Res. 2005 May;66(5):812-7. |
规格 |
50mg 100mg |
单位 |
瓶 |